Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

113.31 -0.22 (-0.19%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 779,885
Open 113.55
Bid (Size) 109.10 (1)
Ask (Size) 115.00 (1)
Prev. Close 113.53
Today's Range 113.06 - 113.66
52wk Range 92.19 - 113.92
Shares Outstanding N/A
Dividend Yield 3.06%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-selling heart-failure drug. The decision pressures Novartis to explore... 
Via Benzinga
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
Via Newsfile
Exposures Product Safety

Performance

YTD
+12.19%
+12.19%
1 Month
+2.52%
+2.52%
3 Month
+10.34%
+10.34%
6 Month
+13.73%
+13.73%
1 Year
+10.97%
+10.97%

More News

Read More
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
Via Benzinga
Exposures Product Safety
Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR.
Via Chartmill
Why NYSE:NVS is a Top Pick for Dividend Investors.
Via Chartmill
Novartis Reports Near 40% Margin In Q2; Shares Slide
Via Investor's Business Daily
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Via FinancialNewsMedia
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Pharma Leader Beats on Earnings, But Shares Fall
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Via The Motley Fool
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
Via Benzinga
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
Via Benzinga
Topics Economy
Exposures Interest Rates
Alnylam Stock Is a Blockbuster Biopharma In the Making
Via InvestorPlace
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
2 Magnificent Stocks to Buy With $500
Via The Motley Fool
D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
3 Global Stocks to Buy to Escape the Volatility on Wall Street
Via InvestorPlace
3 Spinoff Stocks You Should Buy Now: July 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.